Advertisement

High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE

  • Iryna B. Zablotska
  • Stefanie J. Vaccher
  • Mark Bloch
  • Andrew Carr
  • Rosalind Foster
  • Andrew E. Grulich
  • Rebecca Guy
  • Anna McNulty
  • Catriona Ooi
  • Catherine Pell
  • Isobel M. Poynten
  • Garrett Prestage
  • Nathan Ryder
  • David Templeton
  • the PrELUDE Study Group
Original Paper

Abstract

PrELUDE study evaluated daily pre-exposure prophylaxis (PrEP) in high-risk individuals in Australia. This open-label, single-arm study tested participants for HIV/STI and collected behavioural information three-monthly. We report trends over 18 months in medication adherence, side-effects, HIV/STI incidence and behaviour. 320 gay/bisexual men (GBM), 4 women and 3 transgender participants, followed on average 461 days, reported taking seven pills/week on 1,591 (88.5%) occasions and 4-6 pills/week on 153 (8.5%) occasions. No HIV infections were observed. STI incidence was high and stable, while gonorrhoea infections declined from 100.0 to 25.8/100 person-years between 6 and 15 months (p < 0.001). The number of HIV-positive and unknown-status sex partners, and condomless anal intercourse, significantly increased. In this high-risk cohort of mainly GBM, increases in risk behaviours and high STI incidence were not accompanied by HIV infections due to high adherence to daily PrEP. The study informed policy and further PrEP implementation among Australian GBM.

Keywords

Gay and bisexual men HIV prevention Pre-exposure prophylaxis Sexually transmitted infections HIV/STI incidence Side-effects Behaviour 

Notes

Acknowledgements

PRELUDE Study Team: Mark Bloch, Andrew Carr, Ching (Yvonne) Cheung (study clinical coordinator), Rosalind Foster, Chris Gianacas (clinical data manager), Andrew Grulich, Rebecca Guy, Martin Holt, John Kaldor, Brent Mackie, Kenneth Mayer, John McAllister, Anna McNulty, Dean Murphy, Catriona Ooi, Catherine Pell, Isobel Mary Poynten, Garrett Prestage, Nathan Ryder, David Templeton, Stefanie Vaccher (behavioural data manager), John de Wit, Edwina Wright, and Iryna Zablotska (chief investigator and protocol chair). Participating clinics: Clinic 16 at Royal North Shore Hospital, Holdsworth House Medical Practice, Newcastle Sexual Health Service, RPA Sexual Health, St Vincent’s Hospital HIV Immunology and Infectious Diseases Unit, Sydney Sexual Health Centre, Taylor Square Private Clinic, and Western Sydney Sexual Health Centre. Community partner organisations: ACON (formerly AIDS Council of NSW) and Positive Life NSW.

Author Contributions

IBZ, AEG, RG, IMP and GP were involved in the conception and design of the study. IBZ was the Protocol Chair. SJV, MB, AC, RF, AM, CO, CP, NR and DT oversaw participant recruitment and data collection. IBZ and SJV conducted the analysis. IBZ wrote the manuscript with input from all co-authors. All authors met the International Committee of Medical Journal Editors criteria for authorship, and read and approved the final manuscript.

Funding

The study was funded by the NSW Ministry of Health. Gilead Sciences provided the study medication, Truvada®. The views expressed in this publication do not necessarily represent the position of these organisations.

Compliance with Ethical Standards

Ethical Approval

The study protocol was reviewed and approved by the St Vincent’s Hospital Human Research Ethics Committee (HREC) in Sydney, NSW (Protocol #HEPP 1403; identification #HREC/14/SVH/130) and was registered at ClinicalTrials.gov (identifying #NCT02206555).

References

  1. 1.
    UNAIDS—The Joint United Nations Programme on HIV/AIDS. Regional Fact Sheet 2012: North America, Western and Central Europe. 2012; UNAIDS Communications. Available online at unaids.org. Accessed 24 Oct 2013.Google Scholar
  2. 2.
    The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2016. The Kirby Institute, UNSW, Sydney NSW 2052. https://kirby.unsw.edu.au/sites/default/files/kirby/report/SERP_Annual-Surveillance-Report-2016_UPD170627.pdf. Accessed 29 Aug 2017.
  3. 3.
    NSW MInistry of Health. NSW HIV strategy 2012–2015: annual 2014 data report. http://www.health.nsw.gov.au/endinghiv/Documents/annual-2014-hiv-data-report.pdf. Accessed 6 June 2018.
  4. 4.
    Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30(12):1973–83.CrossRefGoogle Scholar
  5. 5.
    Amico KR. The key role of adherence for the effectiveness of antiretroviral-based prevention: state of the science and implications for the Asia-Pacific region. Sexual Health. 2014;11(2):155–65.PubMedGoogle Scholar
  6. 6.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefGoogle Scholar
  7. 7.
    Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefGoogle Scholar
  8. 8.
    World Health Organization. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV. Geneva: WHO; 2012.Google Scholar
  9. 9.
    NSW Government, Ministry of Health. NSW HIV strategy 2012–2015: a new era. Sydney, NSW; 2012. http://www.health.nsw.gov.au/endinghiv/Publications/HIV-strategy.pdf. Accessed 6 June 2018.
  10. 10.
    Food and Drug Administration. Truvada approved to reduce the risk of sexually transmitted HIV in people who are not infected with the virus; 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 20 Sept 2016.
  11. 11.
    Australian Government Department of Health, Therapeutic Goods Administration. Prescription medicines: new or extended uses, or new combinations of registered medicines: extension of Indications’ registrations, Truvada; 2016. https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines. Accessed 1 Jul 2016.
  12. 12.
    Vaccher S, Grulich A, McAllister J, Templeton DJ, Bloch M, McNulty A, et al. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. BMJ Open. 2016;6(6):e012179.CrossRefGoogle Scholar
  13. 13.
    Wright E, Grulich A, Roy K, Boyd M, Cornelisse V, Russell D, O’Donnell D, Witthaker B, Crooks L, Zablotska I. Australasian society for HIV, viral hepatitis and sexual health medicine HIV pre-exposure prophylaxis: clinical guidelines. J Virus Erad. 2017;3:168–84.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Sexually Transmitted Infection Testing Guidelines for Men who have Sex with Men (MSM). Endorsed by the Australian chapter of sexual health medicine. Sexually Transmissible Infections in Gay Men Action Group (STIGMA); 2005.Google Scholar
  15. 15.
    Doblecki-Lewis S, Liu AY, Feaster DJ, Cohen SE, Elion R, Bacon O, et al. Patterns and correlates of participant retention in a multi-city pre-exposure Prophylaxis Demonstration Project. J Acquir Immune Defic Syndr. 2018.  https://doi.org/10.1097/qai.0000000000001724.CrossRefPubMedGoogle Scholar
  16. 16.
    Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903.CrossRefGoogle Scholar
  17. 17.
    Doblecki-Lewis S, Liu A, Feaster D, Cohen SE, Cardenas G, Bacon O, et al. Healthcare access and PrEP continuation in San Francisco and Miami after the US PrEP demo project. J Acquir Immune Defic Syndr. 2017;74(5):531–8.CrossRefGoogle Scholar
  18. 18.
    Rusie LK, Orengo C, Burrell D, Ramachandran A, Houlberg M, Keglovitz K, et al. Preexposure Prophylaxis initiation and retention in care over 5 years, 2012–2017: are quarterly visits too much? Clin Infect Dis. 2018;67(2):283–7.CrossRefGoogle Scholar
  19. 19.
    Haberer JE. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;11(1):10–7.CrossRefGoogle Scholar
  20. 20.
    Sharma S, Babiker AG, Emery S, Gordin FM, Lundgren JD, Neaton JN, et al. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT strategic timing of antiretroviral treatment (START) trial. HIV Med. 2015;16(Suppl 1):30–6.CrossRefGoogle Scholar
  21. 21.
    Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002–8.PubMedGoogle Scholar
  22. 22.
    Liu AY, Hessol NA, Vittinghoff E, Amico KR, Kroboth E, Fuchs J, et al. Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation. AIDS Patient Care STDs. 2014;28(12):622–7.CrossRefGoogle Scholar
  23. 23.
    Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, et al. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc. 2017;20(1):21472.CrossRefGoogle Scholar
  24. 24.
    Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(Suppl 1):S55–60.CrossRefGoogle Scholar
  25. 25.
    Zablotska IB, O’Connor C. Preexposure prophylaxis of HIV infection—the role of clinical practices in ending the HIV epidemic. Curr HIV/AIDS Rep. 2017;14(6):201–10.  https://doi.org/10.1007/s11904-017-0367-7 (Review).CrossRefPubMedGoogle Scholar
  26. 26.
    Grant RM, Albert Liu A, Jen Hecht J, et al. Scale-up of preexposure prophylaxis in San Francisco to impact HIV incidence. CROI 2015. Seattle; February 23–26, 2015. (Abstract 25).Google Scholar
  27. 27.
    Molina J-M. PrEP rollout in France. 21st International AIDS Conference, Durban, symposium, WEWS0804; 2016.Google Scholar
  28. 28.
    Zablotska I. Expanded implementation of PrEP across Australia. International AIDS Conference in Durban, 17–22 July 2016. Oral abstract WEWS0805. http://programme.aids2016.org/. Accessed 2 Jul 2016.
  29. 29.
    Gilead Sciences. Truvada Package Insert; 2016. http://www.gilead.com/pdf/truvada_pi.pdf. Accessed 20 Sept 2016.
  30. 30.
    Vaccher S, Grulich AE, Haire BG, Conway DP, Poynten IM, Ooi C, Foster R, Templeton D, Zablotska IB, on behalf of the PRELUDE Study Team. Validation of participant eligibility for pre-exposure prophylaxis: baseline data from the PRELUDE Demonstration Project. PLoS ONE. 2017;12(9):e0185398.  https://doi.org/10.1371/journal.pone.0185398.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Freeborn K, Portillo CJ. Does Pre-exposure prophylaxis (PrEP) for HIV prevention in men who have sex with men (MSM) change risk behavior? A systematic review. J Clin Nurs. 2017.  https://doi.org/10.1111/jocn.13990.CrossRefGoogle Scholar
  32. 32.
    HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2016. The Kirby Institute, UNSW Australia, Sydney; 2016.Google Scholar
  33. 33.
    Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, et al. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS. 2017;31(12):1709–14.CrossRefGoogle Scholar
  34. 34.
    Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65(5):712–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Iryna B. Zablotska
    • 1
    • 2
  • Stefanie J. Vaccher
    • 1
  • Mark Bloch
    • 3
  • Andrew Carr
    • 4
  • Rosalind Foster
    • 1
    • 5
  • Andrew E. Grulich
    • 1
  • Rebecca Guy
    • 1
  • Anna McNulty
    • 6
  • Catriona Ooi
    • 7
    • 8
  • Catherine Pell
    • 9
  • Isobel M. Poynten
    • 1
  • Garrett Prestage
    • 1
  • Nathan Ryder
    • 10
  • David Templeton
    • 1
    • 11
  • the PrELUDE Study Group
  1. 1.The Kirby InstituteUNSW SydneySydneyAustralia
  2. 2.Sydney Medical School - Westmead, Western Sydney Sexual Health CentreUniversity of SydneyParramattaAustralia
  3. 3.Holdsworth House Medical PracticeSydneyAustralia
  4. 4.St. Vincent’s HospitalSydneyAustralia
  5. 5.Clinic 16 Northern Sydney Sexual HealthRoyal North Shore Community Health CentreSt LeonardsAustralia
  6. 6.Sydney Sexual Health CentreSydneyAustralia
  7. 7.Western Sydney Sexual Health CentreWestern Sydney Local Health DistrictParramattaAustralia
  8. 8.Centre for Infectious Diseases and Microbiology, Westmead Clinical SchoolUniversity of SydneySydneyAustralia
  9. 9.Taylor Square Private PracticeSydneyAustralia
  10. 10.Pacific ClinicNewcastleAustralia
  11. 11.RPA Sexual Health, Sydney Local Health District and Central Clinical SchoolThe University of SydneySydneyAustralia

Personalised recommendations